share_log

Beam Therapeutics analyst ratings

Benzinga Analyst Ratings ·  May 9, 2022 13:14
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
05/09/2022 250.22% SVB Leerink $118 → $121 Maintains Outperform
04/28/2022 79.45% Credit Suisse → $62 Initiates Coverage On → Neutral
01/10/2022 250.22% SVB Leerink $116 → $121 Maintains Outperform
01/05/2022 276.27% Guggenheim → $130 Initiates Coverage On → Buy
11/09/2021 235.75% SVB Leerink $117 → $116 Maintains Outperform
10/19/2021 238.64% SVB Leerink → $117 Initiates Coverage On → Outperform
09/10/2021 334.15% B of A Securities → $150 Initiates Coverage On → Buy
06/29/2021 331.26% Wedbush $114 → $149 Maintains Outperform
05/11/2021 Redburn Partners Initiates Coverage On → Buy
05/04/2021 146.02% RBC Capital → $85 Initiates Coverage On → Sector Perform
03/01/2021 160.49% Barclays $47 → $90 Downgrades Overweight → Equal-Weight
02/16/2021 319.68% Wells Fargo → $145 Initiates Coverage On → Overweight
01/29/2021 189.44% JP Morgan $38 → $100 Downgrades Overweight → Neutral
01/06/2021 143.13% Stifel → $84 Initiates Coverage On → Hold
08/05/2020 -4.49% William Blair → $33 Initiates Coverage On → Outperform
03/02/2020 -7.38% Wedbush → $32 Initiates Coverage On → Outperform
03/02/2020 -7.38% Barclays → $32 Initiates Coverage On → Overweight
03/02/2020 -7.38% Jefferies → $32 Initiates Coverage On → Buy
Data brought to you by Benzinga APIs

Beam Therapeutics Questions & Answers

What is the target price for Beam Therapeutics (BEAM)?

The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by SVB Leerink on May 9, 2022. The analyst firm set a price target for $121.00 expecting BEAM to rise to within 12 months (a possible 250.22% upside). 9 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Beam Therapeutics (BEAM)?

The latest analyst rating for Beam Therapeutics (NASDAQ: BEAM) was provided by SVB Leerink, and Beam Therapeutics maintained their outperform rating.

When is the next analyst rating going to be posted or updated for Beam Therapeutics (BEAM)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Beam Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Beam Therapeutics was filed on May 9, 2022 so you should expect the next rating to be made available sometime around May 9, 2023.

Is the Analyst Rating Beam Therapeutics (BEAM) correct?

While ratings are subjective and will change, the latest Beam Therapeutics (BEAM) rating was a maintained with a price target of $118.00 to $121.00. The current price Beam Therapeutics (BEAM) is trading at is $34.55, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment